Oral MC3R/MC4R dual agonist 710GO drives significant weight loss in male obese primates
Background
The melanocortin system, particularly the melanocortin-4 receptor (MC4R), is crucial for regulating hunger and satiety, making it a prime target for obesity treatment. However, selective MC4R agonists have shown limited clinical success, suggesting that a broader engagement of this pathway might be more effective. This study investigates whether concurrent activation of both melanocortin-3 receptor (MC3R) and MC4R could offer a superior approach to address the unmet need for more potent and comprehensive metabolic disease therapeutics.
Study Design
Researchers developed 710GO, a novel orally available MC3R/MC4R dual agonist, and evaluated its metabolic effects. The study utilized male nonhuman primates and rodents with diet-induced obesity. They compared the efficacy of 710GO against selective MC4R agonism, focusing on primary endpoints such as weight loss and modulation of food intake. The protocol also assessed weight rebound after treatment cessation and evaluated the preclinical safety profile of 710GO, alongside its compatibility with GLP-1-based therapies.
Results
Selective MC3R agonism was found to modulate food intake in a state-dependent manner, highlighting its non-redundant role within the melanocortin system. Crucially, co-agonism of MC3R and MC4R produced greater metabolic effects than selective MC4R agonism alone, indicating cooperative roles for these receptors. Using novel peptides, the orally available dual agonist 710GO was developed. This compound induced significant weight loss in male nonhuman primates with diet-induced obesity. The study also observed that 710GO demonstrated limited weight rebound post-treatment. Furthermore, 710GO showed compatibility with GLP-1-based therapies, suggesting potential for combination strategies, and exhibited a favorable preclinical safety profile. These findings collectively support the enhanced efficacy of combined MC3R/MC4R agonism.
Oral 710GO induced significant weight loss in male nonhuman primates with diet-induced obesity, demonstrating superior metabolic effects compared to selective
MC4Ragonism alone.
Key Findings
- Selective
MC3Ragonism modulates food intake in a state-dependent manner. - Co-agonism of
MC3RandMC4Rproduces greater metabolic effects than selectiveMC4Ragonism alone. - Oral 710GO induced significant weight loss in male nonhuman primates with diet-induced obesity.
- 710GO demonstrated limited weight rebound after treatment cessation.
- 710GO is compatible with
GLP-1-based therapies and has a favorable preclinical safety profile.
Why It Matters
This research introduces 710GO, an orally available MC3R/MC4R dual agonist, as a promising next-generation therapeutic for obesity. The oral route of administration represents a significant practical advantage over injectable peptides, potentially increasing patient adherence and accessibility. The finding that dual agonism is superior to selective MC4R agonism alone suggests a more effective strategy for weight management. Furthermore, its demonstrated compatibility with GLP-1-based therapies opens avenues for novel combination protocols, potentially leading to enhanced weight loss and metabolic improvements beyond what current single-agent therapies can achieve. This could redefine treatment paradigms for individuals struggling with obesity.
obesity
mc3r-agonist
mc4r-agonist
melanocortin-system
weight-loss
food-intake